Zobrazeno 1 - 10
of 658
pro vyhledávání: '"SGLT‐2 inhibitor"'
Publikováno v:
Clinical Case Reports, Vol 12, Iss 9, Pp n/a-n/a (2024)
Key Clinical Message High‐dose acarbose may increase the risk of diabetic ketosis/diabetic ketoacidosis in Asian patients on sodium‐glucose cotransporter‐2 inhibitors. Healthcare providers and patients should be cautious to avoid this combinati
Externí odkaz:
https://doaj.org/article/f82e647bdd0e40918e392880c54f0f60
Autor:
Juan Esteban Gómez-Mesa, Clara Saldarriaga, Alex Arnulfo Rivera-Toquica, Silfredo Arrieta-González, Alfonso Muñoz-Velásquez, Eduardo José Echeverry-Navarrete, Julián Rodrigo Lugo-Peña, Juan Alberto Cerón, Oscar Sveins Rincón-Peña, Luis Eduardo Silva-Diazgranados, Hugo Ernesto Osorio-Carmona, Alejandro Posada-Bastidas, Juan Camilo García, Alejandro David Ochoa-Morón, Luis Eduardo Echeverría
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 53, Iss , Pp 101448- (2024)
Background: The value of Sodium-glucose cotransporter-2 inhibitors (SGLT-2 inhibitor) therapy in individuals with heart failure with preserved EF (HFpEF) was unknown until the EMPEROR-Preserved trial. We aimed to assess the proportion of patients wit
Externí odkaz:
https://doaj.org/article/ab6e7264f06a4dbcbd92f67ee0640f68
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-11 (2024)
Abstract Background We assessed the efficacy and safety of enavogliflozin (0.3 mg), a newly developed SGLT-2 inhibitor, in patients with type 2 diabetes mellitus based on kidney function via pooled analysis of two 24-week, randomized, double-blind ph
Externí odkaz:
https://doaj.org/article/60b24246100e499594c4cfe5d70b4d87
Autor:
Carol Fernandez Hazim, Gustavo Duarte, Ana P Urena, Swati Jain, Rishabh Mishra, Timothy J Vittorio, Miguel Rodriguez-Guerra
Publikováno v:
Drugs in Context, Vol 12, Pp 1-8 (2023)
Diuresis with loop diuretics is the mainstay treatment for volume optimization in patients with congestive heart failure, in which perfusion and volume expansion play a crucial role. There are robust guidelines with extensive evidence for the managem
Externí odkaz:
https://doaj.org/article/f78783fcedfa42df86d332695423703d
Autor:
Hailing Liu
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
ObjectiveTo analyze the clinical characteristics and correlation of Fournier’s gangrene induced by sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors, providing references for safe clinical drug use.MethodsThe CNKI, WanFang, and PubMed data
Externí odkaz:
https://doaj.org/article/f7cf39b727794c67b212e9c1d911118a
Autor:
Vincenzo Trapanese, Francesco Maruca, Maria Resilde Natale, Federica Giofrè, Francesca Cosentino, Silvia Sergi, Giuseppe Armentaro, Valentino Condoleo, Franco Arturi
Publikováno v:
Italian Journal of Medicine, Vol 18, Iss 2 (2024)
Ketoacidosis is considered an emergency metabolic disorder that can be triggered by starvation and alcohol consumption in addition to diabetes. We described an unusual case of ketoacidosis in a non-diabetic young man who presented to our hospital wit
Externí odkaz:
https://doaj.org/article/694667194d824686a1f946aebe839a73
Publikováno v:
Сахарный диабет, Vol 26, Iss 4, Pp 328-333 (2023)
BACKGROUND: Value of diabetes mellitus as social and medical issue seems to be growing worldwide. High rates of concomitant cardiovascular disease represent significant problem for prognosis improvement in diabetes mellitus patients. During analysis
Externí odkaz:
https://doaj.org/article/354bb5f602d449e682d158818ec23c71
Publikováno v:
Medicina, Vol 60, Iss 6, p 991 (2024)
Bacground and Objectives: The objective of this study is to investigate how different therapies modulating insulin resistance, either causally or consequently, affect metabolic parameters in treatment-naïve subjects with T2DM. Subjects and Methods:
Externí odkaz:
https://doaj.org/article/5ee7b3cd4b0545628858a929c667b6ad
Publikováno v:
Antioxidants, Vol 13, Iss 6, p 671 (2024)
Carfilzomib is an irreversible proteasome inhibitor used for multiple myeloma patients. However, carfilzomib treatment is associated with cardiovascular complications. Empagliflozin, an Sodium Glucose Co-transporter 2 inhibitor (SGLT-2) inhibitor, is
Externí odkaz:
https://doaj.org/article/1a14d87c23204f75835e1d182ba538fc
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2024)
BackgroundAngiotensin receptor/neprilysin inhibitor (ARNI) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) have shown a significant protective role against cardiovascular diseases and type 2 diabetes mellitus (T2DM), and there is a growing prop
Externí odkaz:
https://doaj.org/article/6190ea39bc7c45a298be0ebea7ecbb5c